Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AMC Entertainment

Boeing

Monday's big stock charts feature names that buyers went absolutely crazy over.
The post 3 Big Stock Charts for Monday: Boeing, AMC Entertainment, and Moderna appeared first on InvestorPlace.

3 Big Stock Charts for Monday: Boeing, AMC Entertainment, and Moderna

Invacare

Madrigal Pharmaceuticals

Madrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Kansas City Southern

Schlumberger

Moderna, Kansas City Southern, Boeing and Schlumberger were our top stock trades for Monday. That said, here's a look at the charts.

4 Top Stock Trades for Monday: BA, MRNA, SLB, KSU

Moderna news regarding federal funding for the company to advance its possible coronavirus vaccine has MRNA stock rising fast on Friday.
The post Moderna News: MRNA Stock Surges on Potential Coronavirus Vaccine appeared first on InvestorPlace.

Moderna News: MRNA Stock Surges on Potential Coronavirus Vaccine

With Coronavirus rapidly taking the world under its grip, several healthcare companies from across the globe are working committedly to test vaccine candidates and develop an effective vaccine against the flu-like virus. On Thursday, Moderna Inc.

BARDA awards £387 million to Moderna Inc. to ramp-up development of COVID-19 vaccine

The news sent the Massachusetts-based biotech's shares soaring in premarket trading Friday.

Moderna Lands a $483 Million Grant to Accelerate Development of Its Candidate Coronavirus Vaccine

One stock that has been on an upward trajectory since the outbreak of the COVID-19 pandemic is Moderna Inc (NASDAQ: MRNA), a clinical-stage mRNA company.

Moderna Gains More Than 40% This Week: What You Should Know

Moderna stock rocketed Friday after the biotech said it will receive up to $483 million in federal funding for its coronavirus vaccine. Meanwhile, Gilead stock continued to rise.

Covid Report: Moderna Rockets On Vaccine Funding; Leaked Report Prods Gilead

Hope for the best, but prepare for the worst. Investors in Moderna (MRNA) may want to keep that idiom in mind as the company strives to develop a vaccine for the novel coronavirus (Covid-19).

Moderna Banks on Unproven Technology to Develop Covid-19 Vaccine

Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.

Moderna Rallies on US Government Grant for Coronavirus Vaccine

Moderna's COVID-19 vaccine candidate lands a major award from the U.S. Federal government.

Why Moderna Stock Is Rocketing Higher Today

Moderna CEO Stephane Bancel told CNBC on Friday that the funding is critical in aiding manufacturing efforts for their potential vaccine.

Moderna soars after getting $483 million in federal funding for coronavirus vaccine development

Eli Lilly

Regeneron Pharmaceuticals

Sanofi

Vaxart

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Buy 5 Top Medical Stocks on Coronavirus  Drug Trial Results

Though some time in the spotlight is always great, Moderna is set for even better rewards if it wins the coronavirus vaccine race.

What a Potential Coronavirus Vaccine Win Really Means for Moderna

Moderna Inc. (NASDAQ: MRNA) has signed an agreement for a $483 million funding from a federal agency, the biotechnology company announced Thursday.

Moderna Gets $483M Federal Funding For Its Coronavirus Vaccine

Moderna Inc. MRNA, +8.99% said late Thursday that it will receive up to $483 million from the U.S.

Moderna coronavirus vaccine effort to get $483 million in federal funding

Amedisys

Amazon

Chewy

DocuSign

Five9

Masimo

Netflix

Walmart

The COVID-19 pandemic staggered economic activity and decreased consumer spending.

10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic

Inovio Pharmaceuticals

As companies race against time to bring to market a vaccine for the new coronavirus — SARS-CoV-2 — that causes COVID-19, three contenders have emerged as frontrunners, having advanced their candidates into the clinics.

3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know

Moderna, Inc. (NASDAQ: MRNA) shares are trading higher after analysts at multiple firms raised their price targets on the stock.

Why Moderna's Stock Is Trading Higher Today (MRNA)

This biotech will soon start phase 2 trials of its coronavirus vaccine, marking some of the first human trials among all COVID-19 candidates.

Is Moderna a Good Coronavirus Stock To Buy?

With the world under seige from the coronavirus pandemic, an investment like MRNA stock appears incredibly relevant. Still, you should consider some risk factors before diving in.

2 Pros, 2 Cons on MRNA Stock and developing a Coronavirus Vaccine

While three of them are already clinical trials, expect an extended wait before any of them could be available for the general public.

WHO: There Are 70 Coronavirus Vaccines Currently in Development

Based on the company's presentation, its underlying technology works. But questions remain regarding its hopeful SARS-CoV-2 vaccine.

Moderna Releases mRNA Vaccine Data, but Few Details About Its Coronavirus Candidate

Moderna was able to quickly develop a vaccine candidate because Covid-19 is similar to MERS, which it had been working on for two years. 
The post Moderna Stock Is the Greatest Coronavirus Speculation Play appeared first on InvestorPlace.

Moderna Stock Is the Greatest Coronavirus Speculation Play

While MRNA stock makes for a good speculative bet, today's market is far too uncertain to be making risky investments in unproven technology. 
The post Moderna’s Vaccine Race Is Compelling But Risky appeared first on InvestorPlace.

News for Moderna Stock (MRNA)